Literature DB >> 1910691

The CD4-gp120 interaction and AIDS pathogenesis.

D J Capon1, R H Ward.   

Abstract

Infection by the human immunodeficiency virus (HIV) leads to progressive destruction of the CD4+ subset of T lymphocytes, resulting in immunodeficiency and AIDS. The selectivity of CD4+ cell destruction is due to the specific binding of gp120, the external envelope glycoprotein of HIV, to CD4, initiating viral entry. Binding of gp120 to CD4 on the cell surface may also lead to CD4+ cell depletion by inappropriate immune targeting, and may interfere with CD4+ cell function and ontogeny by disrupting CD4-mediated cell signaling. The CD4-gp120 interaction is thus an obvious target for AIDS therapeutics.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1910691     DOI: 10.1146/annurev.iy.09.040191.003245

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  34 in total

1.  The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.

Authors:  Antonella Castagna; Priscilla Biswas; Alberto Beretta; Adriano Lazzarin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Regulation of the serine-base exchange enzyme system by CD4: effects of monoclonal antibodies, jacalin, interleukin 16 and the HIV membrane protein gp120.

Authors:  M J Dumaurier; C Pelassy; J P Breittmayer; C Aussel
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

Review 3.  The macrophage response to HIV-1: Intracellular control of X4 virus replication accompanied by activation of chemokine and cytokine synthesis.

Authors:  Iqbal H Chowdhury; Galina Bentsman; Wonkyu Choe; Mary Jane Potash; David J Volsky
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

4.  Identification of three distinct allelic forms of bovine CD4.

Authors:  W I Morrison; C J Howard; C J Hinson; N D MacHugh; P Sopp
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

5.  Human CD4-major histocompatibility complex class II (DQw6) transgenic mice in an endogenous CD4/CD8-deficient background: reconstitution of phenotype and human-restricted function.

Authors:  R S Yeung; J M Penninger; T M Kündig; Y Law; K Yamamoto; N Kamikawaji; L Burkly; T Sasazuki; R Flavell; P S Ohashi; T W Mak
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

6.  Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction.

Authors:  H J Ryser; E M Levy; R Mandel; G J DiSciullo
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

7.  A monoclonal antibody to the CDR-3 region of CD4 inhibits soluble CD4 binding to virions of human immunodeficiency virus type 1.

Authors:  J P Moore
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

8.  Analysis of the basis of resistance and susceptibility of CD4+ T cells to human immunodeficiency virus (HIV)-gp120 induced anergy.

Authors:  A Faith; R E O'Hehir; M Malkovsky; J R Lamb
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

9.  Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites.

Authors:  Alexander Berchanski; Aviva Lapidot
Journal:  J Mol Model       Date:  2008-12-05       Impact factor: 1.810

10.  Human immunodeficiency virus type 1 envelope glycoprotein molecules containing membrane fusion-impairing mutations in the V3 region efficiently undergo soluble CD4-stimulated gp120 release.

Authors:  E A Berger; J R Sisler; P L Earl
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.